Related Experiment Video
Updated: Jul 5, 2026
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
A randomised controlled trial comparing StarClose and AngioSeal vascular closure devices in a district general
R A Veasey1, J K Large, J Silberbauer
1Cardiac Department, Eastbourne District General Hospital, King's Drive, Eastbourne, UK.
Insights
StarClose and AngioSeal vascular closure devices (VCDs) offer similar haemostasis after cardiac catheterisation. StarClose resulted in less bruising at one week, with comparable complication rates and patient satisfaction.
Area of Science:
- Cardiology
- Vascular Surgery
- Medical Devices
Background:
- Vascular closure devices (VCDs) like AngioSeal and StarClose facilitate haemostasis after femoral artery procedures.
- These devices offer advantages over manual pressure, reducing time to haemostasis and ambulation.
Purpose of the Study:
- To compare the efficacy and safety of AngioSeal VIP and StarClose VCDs in patients undergoing elective coronary angiography.
- To evaluate post-procedure bruising, patient satisfaction, and complication rates between the two VCDs.
Main Methods:
- A prospective, randomized trial involving 401 patients undergoing elective coronary angiography.
- Patients received either AngioSeal VIP or StarClose VCD, followed by immediate mobilization.
- Bruising, patient satisfaction, pain perception, and complications were assessed at various time points.
Main Results:
- Arteriotomy closure success rates were similar between AngioSeal (69.2%) and StarClose (69.3%).
- No significant bruising was observed at 30 or 60 minutes post-procedure.
- Significantly less bruising occurred at 1 week with StarClose (38.5 cm²) compared to AngioSeal (63.1 cm²; p=0.02).
- Patient satisfaction and pain perception were comparable between groups.
- Deployment success and mobilization rates were lower for junior operators.
Conclusions:
- Both AngioSeal and StarClose achieve similar haemostasis following cardiac catheterisation.
- StarClose demonstrates a significant reduction in bruising at one week compared to AngioSeal.
- No significant differences in complication rates, patient satisfaction, or pain perception were found between the two devices.
Aims:
AngioSeal and StarClose are vascular closure devices (VCDs) that can be used following cardiac catheterisation via the femoral artery to achieve haemostasis. Both devices have been demonstrated to be superior to conventional manual pressure, which reduce time to haemostasis and time to patient ambulation. We sought to compare these devices in a prospective, randomised trial.
Methods:
Patients undergoing elective coronary angiography were randomised to receive either AngioSeal VIP or StarClose VCD with immediate postprocedure mobilisation. Bruising was recorded at 30 min, 60 min and at 1 week postprocedure. Patient satisfaction surveys were taken at 1 h and 1 week postprocedure. Complications for both groups were compared.
Results:
Four hundred and one patients were included. Arteriotomy closure was achieved in 144 of 208 (69.2%) patients randomised to AngioSeal and 134 of 193 (69.3%) patients randomised to StarClose (p = ns). There was no significant bruising in either group at either 30 or 60 min postprocedure. However, at 1 week, there was significantly more bruising in the AngioSeal group than the StarClose group (63.1 vs. 38.5cm2, p = 0.02). Patient satisfaction and pain perception with the procedure at closure were not significantly different between the groups. Deployment success and instant mobilisation rates were significantly lower for junior, as compared with senior, operators.
Conclusion:
Achievement of haemostasis is similar with both AngioSeal and StarClose. The StarClose vascular closure device results in significantly less bruising at 1 week postprocedure as compared with AngioSeal, with no significant differences in complication rates. Patients' pain perception and satisfaction are similar with both VCDs.
